DirectMeds: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://directmeds.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.

1. 1

   “"If you've looked into brand-name versions of semaglutide, you know the cost can be steep – especially without insurance. That's where buying compounded semaglutide online can make a big difference. Compounded medications are created by licensed compounding pharmacies using the same active ingredients."”

2. 2

   “"Compounded semaglutide contains the same active ingredient as branded semaglutide."”

3. 3

   “"Don't give up hope if brand-name Mounjaro is out of reach due to cost. You may be able to get compounded tirzepatide online, which is an effective and budget-friendly alternative. Compounded formulations use the same active ingredient as the brand-name drug, customized by licensed compounding pharmacies to meet your needs."”

4. 4

   “Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not.”

1. 1

   Letter issued

   September 2025

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

directmeds.com returned a live storefront when we checked in August 2026, still marketing GLP-1 medications under the same DirectMeds branding named in the FDA letter.

This is the letter in our roster closest to Doseworth's own beat: DirectMeds marketed its compounded price as a budget alternative to the branded drug on the strength of "same active ingredient" language. FDA's objection is to that comparison, not to the price itself — it says nothing about whether DirectMeds' pricing is accurate or fair, only that the same-as-the-brand pitch overstated what FDA has evaluated.

Doseworth’s review of DirectMeds has the pricing, the states served, and what’s included.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence DirectMeds failed to respond.